Peptides From China Catalog Customization Blog How It Works How to Pay Track Order FAQ Contact News

5-Amino-1MQ: NNMT Inhibition in Preclinical Research (RUO)

What preclinical research shows about 5-Amino-1MQ and NNMT inhibition. Research use only — no human dosing, mg/day figures, or administration guidance.

What Is 5-Amino-1MQ

5-Amino-1MQ (5-amino-1-methylquinolinium) is a small-molecule NNMT (nicotinamide N-methyltransferase) inhibitor studied for its effects on cellular metabolism. It is supplied for research use only (RUO) and is not for human or veterinary use.

NNMT activity is linked to:

  • NAD⁺ metabolism

  • methyl donor balance (SAM/SAH)

  • adipocyte energy handling

Preclinical work associates NNMT inhibition with increased energy expenditure and reduced fat accumulation in model systems. Most data to date is in vitro and animal-based.

Why Route of Administration Matters in Study Design

Searches like “5 amino 1mq dosage” mix very different contexts. In model systems, systemic exposure differs by route: oral delivery is subject to first-pass metabolism and lower bioavailability, while parenteral delivery in experimental animal settings produces higher systemic exposure per unit mass. PFC does not publish human dosing, mg/day figures, administration instructions, or reconstitution protocols.

What Research Actually Shows

Preclinical studies, primarily in rodents, indicate that NNMT inhibition via compounds in this class can increase cellular energy expenditure, reduce adiposity, and alter methylation-related pathways. Exposure in animal models is reported in mg/kg of body weight and does not translate to human contexts.

Why More Is Not Necessarily Better

5-Amino-1MQ acts by interfering with NNMT activity, which is connected to NAD⁺ metabolism and methyl donor balance. Excessive inhibition may theoretically affect methylation capacity and nicotinamide handling, so increasing exposure does not necessarily produce linear effects in model systems.

Formulation and Quality Considerations

With small molecules like 5-Amino-1MQ, experimental consistency depends on compound purity, the salt or form used, stability in solution, and manufacturing accuracy. Product specifications should be reviewed for the applicable purity information. Differences in formulation can significantly affect observed outcomes between batches.

Limitations of the Available Data

  • No standardized clinical dosing guidelines exist

  • Most data is preclinical

  • Human data is limited

  • Figures circulating online are extrapolated, not validated

FAQ

Does PFC publish a 5-Amino-1MQ dosage?

No. This material is for research use only and PFC does not provide human dosing, mg/day figures, administration instructions, or reconstitution protocols.

Is there a standard clinical dose?

No. There are no established clinical dosing guidelines for this compound.

Why does route of administration matter in study design?

Systemic exposure per unit mass differs by route in model systems, so results are not comparable across routes.

Disclaimer

This content is provided for informational and educational purposes only and is intended for research discussion. All material is for research use only (RUO). It does not provide medical advice, treatment recommendations, dosing guidance, or instructions for human use. Interpretation should be based on available research and conducted under appropriate scientific oversight.

Related Products